OCT 28, 2020 7:00 AM PDT

Guiding pancreatic cancer therapy by individualized epigenetics

Sponsored by: Agilent
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Senior Research Scientist, Dartmouth-Hitchcock Norris Cotton Cancer Center
    Biography
      Dr. Surajit Dhara is a Senior Research Scientist at Dartmouth-Hitchcock Norris Cotton Cancer Center in Lebanon, New Hampshire. His focus as a cancer biologist has been in the areas of experimental therapeutics and development of biomarkers for precision therapy in malignant diseases. His most recent accomplishment is the discovery of an epigenetic biomarker for individualized therapy in pancreatic ductal adenocarcinoma (PDAC) through a multidisciplinary collaborative project that included experts from both academia and industry. Dr Dhara did a postdoc at Johns Hopkins University where he focused on therapeutic opportunities related to the hedgehog signaling pathway and how de novo mutations may occur through the cancer treatment process. Following this work, he was a part of the National Institute of Biomedical Genomics, the institute driving the International Cancer Genome Consortium (ICGC) India project. As a Principal Investigator he pursued clonal evolution of tumor cells under the selection pressure of chemotherapy using next-generation sequencing technologies. With his research team he developed clinical resources both in Head & Neck cancers and Glioblastoma Multiforme (GBM). He led a multidisciplinary project on epigenetic biomarker discovery in pancreatic ductal adenocarcinoma (PDAC) at the Rubenstein Center for Pancreas Research in Memorial Sloan Kettering Cancer Center, New York. Here he and the team investigated tumor-cell intrinsic epigenetic patterns of PDAC by ATAC-seq technology, instead of the traditional approach of using bulk tumors. This led to the discovery of a chromatin accessibility signature predicting prognosis of PDAC. Next Dr Dhara and the team invented a novel microarray technology called “ATAC-array”, a technology suitable in the future for clinical diagnostics. Dr Dhara’s immediate goal is develop precision oncology technologies that will deliver better outcomes and better quality of life for cancer patients.
    • Global Product Manager Microarrays

    Abstract
    Date:  October 28, 2020
    Time: 7:00am (PDT),  10:00am (EDT)
     
    Although chemotherapy remains the mainstay of systemic therapy, a large number of cancer patients fail to respond to it. About half of surgically resected pancreatic ductal adenocarcinoma (PDAC) patients relapse within a year despite adjuvant chemotherapy. By investigating tumor-cell-intrinsic chromatin accessibility patterns of resected PDAC, we discovered a signature of 1092 chromatin loci displaying differential accessibility between patients with disease free survival (DFS) < 1 year and patients with DFS > 1 year. Based on this signature, we developed “ATAC-array” – the only microarray that reads chromatin accessibility – a convenient platform obviating the time and cost of Next Generation Sequencing. We also identified HNF1b, a transcription factor displaying differential nuclear localization between patients with short vs. long DFS. Combining these two simple methodologies, ATAC-array “Prognosis Score” and HNF1b nuclear localization, we have developed an algorithm which we call PancEpistemeDx, and stratified PDAC patients into prognostic groups with up to four-fold differences in DFS. Whether adverse patterns of chromatin accessibility might assist in the selection of PDAC patients for epigenetic “reprogramming” therapy remains to be determined, but our stratification provides a simple and clinically achievable prediction of favorable vs unfavorable epigenetic states in PDAC. Episteme Prognostics aims to 1) optimize PancEpistemeDx for routine clinical use and expand it to all stages of pancreatic cancer, and 2) develop companion diagnostics (CDx) for epigenetic drugs. We sit at the dawn of the epigenetic drug discovery era, the FDA has already approved 9 epigenetic drugs, and currently, 138 clinical trials on epigenetic drugs are registered by 31 different pharmaceutical companies. Our technology can support therapeutic decision-making in pancreatic cancer clinics, as well as can support clinical trials on epigenetic drug discovery for pharma companies.
     
    Learning Objectives:
    • How epigenetics adds an important layer of information on top of genetic mutations to inform cancer research
    • How microarray analysis may reveal innovative approaches to deliver companion diagnostics in the future
    • How epigenetics may be used as a novel approach to drug discovery
     
    For Research Use Only. Not for use in diagnostic procedures.
     
     
    Webinars will be available for unlimited on-demand viewing after live event.
     
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 10, 2020 7:00 AM PST
    C.E. CREDITS
    NOV 10, 2020 7:00 AM PST
    DATE: November 10, 2020 TIME: 7:00am PDT, 10:00am EDT Automation can provide tremendous benefits such as increased pipetting precision and accuracy, productivity, and throughput. Numerous wo...
    Loading Comments...
    Show Resources
    Attendees
    • See more